Keywords
Last Name
Institution

C. Warren Olanow

TitlePROFESSOR
InstitutionMount Sinai
DepartmentNeurology
Address5 East 98th Street
1st Floor
New York NY 10029
Phone212-241-8435
Fax646-537-9690
    Other Positions
    TitlePROFESSOR
    InstitutionMount Sinai
    DepartmentNeuroscience


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Olanow CW, Schapira AH. Therapeutic prospects for Parkinson disease. Ann Neurol. 2013 Sep; 74(3):337-47.
      View in: PubMed
    2. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
      View in: PubMed
    3. Bézard E, Olanow CW, Obeso JA. Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration. Mov Disord. 2013 Jul; 28(8):1023-4.
      View in: PubMed
    4. Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, Siderowf A, Schapira AH, Oertel W, Obeso JA, Olanow CW, Poewe W, Stern M. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol. 2013 May; 12(5):514-24.
      View in: PubMed
    5. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 2013 Apr 30; 80(18):1698-701.
      View in: PubMed
    6. Stocchi F, Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):3-7.
      View in: PubMed
    7. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord. 2013 Jan; 28(1):31-40.
      View in: PubMed
    8. Olanow CW, Obeso JA, Stocchi F. The vatican meeting on neuroprotection for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):1-2.
      View in: PubMed
    9. Olanow CW, Isacson O. Stem cells for Parkinson's disease: advancing science but protecting patients. Mov Disord. 2012 Oct; 27(12):1475-7.
      View in: PubMed
    10. Olanow CW. A colonic biomarker of Parkinson's disease? Mov Disord. 2012 May; 27(6):674-6.
      View in: PubMed
    11. Olanow CW, Obeso JA. The significance of defining preclinical or prodromal Parkinson's disease. Mov Disord. 2012 Apr 15; 27(5):666-9.
      View in: PubMed
    12. Alegre M, Hallett M, Olanow CW, Obeso JA. Technical advances in deep brain stimulation: how far is enough? Mov Disord. 2012 Mar; 27(3):341-2.
      View in: PubMed
    13. Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol. 2012 Jan-Feb; 35(1):15-20.
      View in: PubMed
    14. Olanow CW. Medical therapy for Parkinson's disease - the current state of the art. Rinsho Shinkeigaku. 2012; 52(11):890.
      View in: PubMed
    15. Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012 Feb; 27(2):284-8.
      View in: PubMed
    16. Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology. 2011 Oct 11; 77(15):1416-7.
      View in: PubMed
    17. Alterman RL, Tagliati M, Olanow CW. Open-label surgical trials for Parkinson disease: time for reconsideration. Ann Neurol. 2011 Jul; 70(1):5-8.
      View in: PubMed
    18. Hälbig TD, Assuras S, Creighton J, Borod JC, Tse W, Frisina PG, Voustianiouk A, Gracies JM, Olanow CW. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease. Mov Disord. 2011 Aug 1; 26(9):1677-83.
      View in: PubMed
    19. Olanow CW, Obeso JA. Movement disorders 2011--the state of the journal. Mov Disord. 2011 Jun; 26(7):1183-4.
      View in: PubMed
    20. Hälbig TD, Creighton J, Assuras S, Borod JC, Tse W, Gracies JM, Foldi NS, Kaufmann H, Olanow CW, Voustianiouk A. Preserved emotional modulation of motor response time despite psychomotor slowing in young-old adults. Int J Neurosci. 2011 Aug; 121(8):430-6.
      View in: PubMed
    21. Olanow CW, Wunderle KB, Kieburtz K. Milestones in movement disorders clinical trials: advances and landmark studies. Mov Disord. 2011 May; 26(6):1003-14.
      View in: PubMed
    22. Olanow CW, McNaught K. Parkinson's disease, proteins, and prions: milestones. Mov Disord. 2011 May; 26(6):1056-71.
      View in: PubMed
    23. Hälbig TD, Borod JC, Frisina PG, Tse W, Voustianiouk A, Olanow CW, Gracies JM. Emotional processing affects movement speed. J Neural Transm. 2011 Sep; 118(9):1319-22.
      View in: PubMed
    24. Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
      View in: PubMed
    25. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM, Olanow CW, Mufson EJ, Kordower JH. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
      View in: PubMed
    26. Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-72.
      View in: PubMed
    27. Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD--a road map for moving forward. Mov Disord. 2010 Sep 15; 25(12):1774-9.
      View in: PubMed
    28. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
      View in: PubMed
    29. Olanow CW, Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology. 2010 Apr 6; 74(14):1149-50.
      View in: PubMed
    30. Obeso JA, Olanow CW. A changing journal for a changing field. Mov Disord. 2010 Feb 15; 25(3):255-6.
      View in: PubMed
    31. Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord. 2010 Feb 15; 25(3):377-84.
      View in: PubMed
    32. Cho C, Kunin M, Kudo K, Osaki Y, Olanow CW, Cohen B, Raphan T. Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait. J Neurophysiol. 2010 Mar; 103(3):1478-89.
      View in: PubMed
    33. Olanow CW, Kordower JH, Lang AE, Obeso JA. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009 Nov; 66(5):591-6.
      View in: PubMed
    34. Olanow CW, Kordower JH. Modeling Parkinson's disease. Ann Neurol. 2009 Oct; 66(4):432-6.
      View in: PubMed
    35. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
      View in: PubMed
    36. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A. 2009 Aug 4; 106(31):12571-2.
      View in: PubMed
    37. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
      View in: PubMed
    38. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009 May 26; 72(21 Suppl 4):S1-136.
      View in: PubMed
    39. Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology. 2009 Feb 17; 72(7 Suppl):S59-64.
      View in: PubMed
    40. Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
      View in: PubMed
    41. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
      View in: PubMed
    42. Olanow CW, Stern MB. Parkinson's disease: unresolved issues. Ann Neurol. 2008 Dec; 64 Suppl 2:S1-2.
      View in: PubMed
    43. Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S47-55.
      View in: PubMed
    44. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol. 2008 Dec; 64 Suppl 2:S101-10.
      View in: PubMed
    45. Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temiño B, Mena-Segovia J, Rodríguez M, Olanow CW. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol. 2008 Dec; 64 Suppl 2:S30-46.
      View in: PubMed
    46. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
      View in: PubMed
    47. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
      View in: PubMed
    48. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
      View in: PubMed
    49. Nair VD, Olanow CW. Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem. 2008 May 30; 283(22):15469-78.
      View in: PubMed
    50. Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008 May; 7(5):400-8.
      View in: PubMed
    51. Olanow CW. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions. Mov Disord. 2008; 23 Suppl 3:S613-22.
      View in: PubMed
    52. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord. 2008; 23 Suppl 3:S599-612.
      View in: PubMed
    53. Olanow CW, Lees A, Obeso J. Levodopa therapy for Parkinson's disease: challenges and future prospects. Mov Disord. 2008; 23 Suppl 3:S495-6.
      View in: PubMed
    54. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec; 22(16):2314-24.
      View in: PubMed
    55. Olanow CW. The pathogenesis of cell death in Parkinson's disease--2007. Mov Disord. 2007 Sep; 22 Suppl 17:S335-42.
      View in: PubMed
    56. Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007 Sep-Oct; 30(5):287-94.
      View in: PubMed
    57. Kordower JH, Olanow CW. Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol. 2008 Jan; 209(1):34-40.
      View in: PubMed
    58. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007 Aug 15; 22(11):1623-9.
      View in: PubMed
    59. Perl DP, Olanow CW. The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol. 2007 Aug; 66(8):675-82.
      View in: PubMed
    60. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem. 2007 Oct; 103(1):238-47.
      View in: PubMed
    61. Tse W, Libow LS, Neufeld R, Lesser G, Frank J, Dolan S, Tarshish C, Gracies JM, Olanow CW, Koller WC, Hälbig TD. Prevalence of movement disorders in an elderly nursing home population. Arch Gerontol Geriatr. 2008 May-Jun; 46(3):359-66.
      View in: PubMed
    62. Kieburtz K, Olanow CW. Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy. Mt Sinai J Med. 2007 Apr; 74(1):7-14.
      View in: PubMed
    63. Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
      View in: PubMed
    64. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
      View in: PubMed
    65. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2006 Dec; 5(12):1013-20.
      View in: PubMed
    66. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord. 2006 Nov; 21(11):1806-23.
      View in: PubMed
    67. Nair VD, McNaught KS, González-Maeso J, Sealfon SC, Olanow CW. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem. 2006 Dec 22; 281(51):39550-60.
      View in: PubMed
    68. McNaught KS, Olanow CW. Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol. 2006 Aug; 60(2):243-7.
      View in: PubMed
    69. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006 Aug; 5(8):677-87.
      View in: PubMed
    70. Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol. 2006 Jul; 2(7):382-92.
      View in: PubMed
    71. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006 Jul; 21(7):916-23.
      View in: PubMed
    72. McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S37-49.
      View in: PubMed
    73. Dass B, Olanow CW, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
      View in: PubMed
    74. Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S69-79.
      View in: PubMed
    75. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S24-36.
      View in: PubMed
    76. Cho C, Osaki Y, Kunin M, Cohen B, Olanow CW, Raphan T. A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulation. Conf Proc IEEE Eng Med Biol Soc. 2006; 1:1228-31.
      View in: PubMed
    77. Olanow CW. Movement disorders: a step in the right direction. Lancet Neurol. 2006 Jan; 5(1):3-5.
      View in: PubMed
    78. McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging. 2006 Apr; 27(4):530-45.
      View in: PubMed
    79. Olanow CW. Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. Arch Neurol. 2005 Sep; 62(9):1343-4.
      View in: PubMed
    80. Snyder BJ, Olanow CW. Stem cell treatment for Parkinson's disease: an update for 2005. Curr Opin Neurol. 2005 Aug; 18(4):376-85.
      View in: PubMed
    81. Tse W, Liu Y, Barthlen GM, Hälbig TD, Tolgyesi SV, Gracies JM, Olanow CW, Koller WC. Clinical usefulness of the Parkinson's disease sleep scale. Parkinsonism Relat Disord. 2005 Aug; 11(5):317-21.
      View in: PubMed
    82. Lang AE, Miyasaki J, Olanow CW, Stoessl AJ, Suchowersky O. Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. Can J Neurol Sci. 2005 Aug; 32(3):277-86.
      View in: PubMed
    83. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005 Jun; 62(6):905-10.
      View in: PubMed
    84. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005; 20 Suppl 11:S3-10.
      View in: PubMed
    85. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9; 351(24):2498-508.
      View in: PubMed
    86. Shashidharan P, Sandu D, Potla U, Armata IA, Walker RH, McNaught KS, Weisz D, Sreenath T, Brin MF, Olanow CW. Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet. 2005 Jan 1; 14(1):125-33.
      View in: PubMed
    87. Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, Olanow CW. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm. 2004 Oct; 111(10-11):1237-51.
      View in: PubMed
    88. Hälbig TD, Tse W, Olanow CW. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats. Neurol Clin. 2004 Oct; 22(3 Suppl):S1-S17.
      View in: PubMed
    89. Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004 Oct; 61(10):1563-8.
      View in: PubMed
    90. McNaught KS, Kapustin A, Jackson T, Jengelley TA, Jnobaptiste R, Shashidharan P, Perl DP, Pasik P, Olanow CW. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol. 2004 Oct; 56(4):540-7.
      View in: PubMed
    91. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. 2004 Sep; 19(9):997-1005.
      View in: PubMed
    92. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004 Aug; 3(8):496-503.
      View in: PubMed
    93. Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W. Movement disorders and AIDS: a review. Parkinsonism Relat Disord. 2004 Aug; 10(6):323-34.
      View in: PubMed
    94. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004 Aug; 19(8):916-23.
      View in: PubMed
    95. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol. 2004 Jul; 56(1):149-62.
      View in: PubMed
    96. Germano IM, Gracies JM, Weisz DJ, Tse W, Koller WC, Olanow CW. Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study. J Neurosurg. 2004 Jul; 101(1):36-42.
      View in: PubMed
    97. Olanow CW. Melvin David Yahr, MD (1917-2004). Neurology. 2004 Jun 8; 62(11):1932-3.
      View in: PubMed
    98. Nair VD, Yuen T, Olanow CW, Sealfon SC. Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress. J Biol Chem. 2004 Jun 25; 279(26):27494-501.
      View in: PubMed
    99. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
      View in: PubMed
    100. Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci. 2004 Mar; 1012:209-23.
      View in: PubMed
    101. Shashidharan P, Paris N, Sandu D, Karthikeyan L, McNaught KS, Walker RH, Olanow CW. Overexpression of torsinA in PC12 cells protects against toxicity. J Neurochem. 2004 Feb; 88(4):1019-25.
      View in: PubMed
    102. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004 Jan 21; 291(3):358-64.
      View in: PubMed
    103. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology. 2004 Jan 13; 62(1 Suppl 1):S56-63.
      View in: PubMed
    104. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology. 2004 Jan 13; 62(1 Suppl 1):S72-81.
      View in: PubMed
    105. Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med. 2004; 55:41-60.
      View in: PubMed
    106. Kramer BC, Yabut JA, Cheong J, Jnobaptiste R, Robakis T, Olanow CW, Mytilineou C. Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur J Neurosci. 2004 Jan; 19(2):280-6.
      View in: PubMed
    107. Olanow CW. Present and future directions in the management of motor complications in patients with advanced PD. Neurology. 2003 Sep 23; 61(6 Suppl 3):S24-33.
      View in: PubMed
    108. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
      View in: PubMed
    109. Roth T, Rye DB, Borchert LD, Bartlett C, Bliwise DL, Cantor C, Gorell JM, Hubble JP, Musch B, Olanow CW, Pollak C, Stern MB, Watts RL. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med. 2003 Jul; 4(4):275-80.
      View in: PubMed
    110. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J. 2003 Jul 1; 373(Pt 1):25-32.
      View in: PubMed
    111. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord. 2003 Jun; 18(6):668-72.
      View in: PubMed
    112. Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord. 2003 Mar; 9(4):221-4.
      View in: PubMed
    113. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther. 2003 Feb; 304(2):792-800.
      View in: PubMed
    114. Olanow CW. Dietary vitamin E and Parkinson's disease: something to chew on. Lancet Neurol. 2003 Feb; 2(2):74.
      View in: PubMed
    115. Olanow CW, Schapira AH, Agid Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol. 2003; 53 Suppl 3:S1-2.
      View in: PubMed
    116. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003 Jan; 179(1):38-46.
      View in: PubMed
    117. Schapira AH, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S149-57; discussion S157-9.
      View in: PubMed
    118. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S73-84; discussion S84-6.
      View in: PubMed
    119. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol. 2003; 53 Suppl 3:S87-97; discussion S97-9.
      View in: PubMed
    120. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002 Dec; 16(11):2136-48.
      View in: PubMed
    121. Olanow CW. Surgical therapy for Parkinson's disease. Eur J Neurol. 2002 Nov; 9 Suppl 3:31-9.
      View in: PubMed
    122. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. 2002 Sep; 125(Pt 9):2058-66.
      View in: PubMed
    123. McNaught KS, Björklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 2002 Aug 7; 13(11):1437-41.
      View in: PubMed
    124. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett. 2002 Jul 5; 326(3):155-8.
      View in: PubMed
    125. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May; 51(5):604-12.
      View in: PubMed
    126. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem. 2002 Apr; 81(2):301-6.
      View in: PubMed
    127. Olanow CW. The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology. 2002 Feb 26; 58(4 Suppl 1):S33-41.
      View in: PubMed
    128. Kramer BC, Yabut JA, Cheong J, JnoBaptiste R, Robakis T, Olanow CW, Mytilineou C. Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection. Neuroscience. 2002; 114(2):361-72.
      View in: PubMed
    129. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun; 56(11 Suppl 5):S1-S88.
      View in: PubMed
    130. Olanow CW, Brin MF. Surgical therapies for Parkinson's disease. A physician's perspective. Adv Neurol. 2001; 86:421-33.
      View in: PubMed
    131. Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci. 2000 Oct; 23(10 Suppl):S34-40.
      View in: PubMed
    132. Shashidharan P, Good PF, Hsu A, Perl DP, Brin MF, Olanow CW. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 2000 Sep 22; 877(2):379-81.
      View in: PubMed
    133. Morrison CE, Borod JC, Brin MF, Raskin SA, Germano IM, Weisz DJ, Olanow CW. A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data. Neuropsychiatry Neuropsychol Behav Neurol. 2000 Jul; 13(3):204-19.
      View in: PubMed
    134. Olanow CW, Stocchi F. Why delaying levodopa is a good treatment strategy in early Parkinson's disease. Eur J Neurol. 2000 May; 7 Suppl 1:3-8.
      View in: PubMed
    135. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol. 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8.
      View in: PubMed
    136. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord. 2000 Mar; 15(2):212-5.
      View in: PubMed
    137. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol. 2000 Feb; 57(2):263-7.
      View in: PubMed
    138. Shashidharan P, Kramer BC, Walker RH, Olanow CW, Brin MF. Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res. 2000 Jan 24; 853(2):197-206.
      View in: PubMed
    139. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology. 2000; 55(11 Suppl 4):S72-7; discussion S78-81.
      View in: PubMed
    140. Olanow CW, Brin MF, Obeso JA. The role of deep brain stimulation as a surgical treatment for Parkinson's disease. Neurology. 2000; 55(12 Suppl 6):S60-6.
      View in: PubMed
    141. Olanow CW. A rational approach to the treatment of early Parkinson's disease. Parkinsonism Relat Disord. 1999 Dec; 5(4):217-20.
      View in: PubMed
    142. Mytilineou C, Kokotos Leonardi ET, Kramer BC, Jamindar T, Olanow CW. Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. J Neurochem. 1999 Jul; 73(1):112-9.
      View in: PubMed
    143. Walker RH, Spiera H, Brin MF, Olanow CW. Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. Mov Disord. 1999 Mar; 14(2):262-8.
      View in: PubMed
    144. Tatton WG, Olanow CW. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta. 1999 Feb 9; 1410(2):195-213.
      View in: PubMed
    145. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol. 1998 Sep; 44(3 Suppl 1):S142-8.
      View in: PubMed
    146. Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology. 1998 Sep; 51(3):825-30.
      View in: PubMed
    147. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol. 1998 Sep; 44(3 Suppl 1):S167-74.
      View in: PubMed
    148. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol. 1998 Apr; 57(4):338-42.
      View in: PubMed
    149. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology. 1998 Mar; 50(3 Suppl 3):S1-57.
      View in: PubMed
    150. Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther. 1998 Feb; 284(2):700-6.
      View in: PubMed
    151. Olanow CW, Mytilineou C, Tatton W. Current status of selegiline as a neuroprotective agent in Parkinson's disease. Mov Disord. 1998; 13 Suppl 1:55-8.
      View in: PubMed
    152. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology. 1997 Jul; 49(1 Suppl 1):S26-33.
      View in: PubMed
    153. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem. 1997 Jan; 68(1):33-9.
      View in: PubMed
    154. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 1997 Jan; 68(1):434-6.
      View in: PubMed
    155. Olanow CW. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology. 1996 Dec; 47(6 Suppl 3):S210-6.
      View in: PubMed
    156. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol. 1996 Jul; 149(1):21-8.
      View in: PubMed
    157. Olanow CW. A 61-year-old man with Parkinson's disease. JAMA. 1996 Mar 6; 275(9):716-22.
      View in: PubMed
    158. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 1996 Mar; 19(3):102-9.
      View in: PubMed
    159. Olanow CW. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J Neural Transm Suppl. 1996; 48:75-84.
      View in: PubMed
    160. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol. 1994 Dec; 7(6):548-58.
      View in: PubMed
    Olanow's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067